E77.1
Defects in glycoprotein degradation
Clinical Classification Guidelines
Inclusion Terms
- Aspartylglucosaminuria
- Fucosidosis
- Mannosidosis
- Sialidosis [mucolipidosis I]
Medical Intelligence & Overview
ICD-10 code E77.1 refers to conditions characterized by abnormalities in the breakdown of glycoproteins, which are complex molecules involved in various biological processes. These defects often lead to the accumulation of certain substances in the body, resulting in various health issues. Specific disorders under this code include Aspartylglucosaminuria, Fucosidosis, Mannosidosis, and Sialidosis (also known as Mucolipidosis I), each with distinct features but sharing a common problem with glycoprotein processing.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting enzymes responsible for glycoprotein breakdown Inherited deficiencies that impair metabolic pathways involved in lysosomal degradation Alterations in genes encoding for specific lysosomal enzymes specific to each disorder
Key Symptoms: Progressive neurodegeneration leading to developmental delays Coarse facial features and skeletal abnormalities Hearing loss or vision problems Enlarged liver or spleen (hepatosplenomegaly) Cardiac issues in some cases Growth delays and intellectual disability Muscle weakness or coordination problems
Diagnostic & Treatment
Diagnosis Path: Diagnosis often involves a combination of clinical evaluation, biochemical testing to detect enzyme activity levels, and genetic testing to identify mutations. Urinary tests may reveal abnormal substances that accumulate due to defective degradation mechanisms. Imaging studies can also be used to assess organ involvement and progression of the disease.
Treatment Protocols: Current treatments primarily focus on managing symptoms and improving quality of life. Some approaches include enzyme replacement therapy in select cases, supportive therapies such as physical and occupational therapy, and symptomatic treatments for neurological and organ-related issues. Participation in clinical trials may provide access to emerging therapies. Early diagnosis and intervention are important for better health outcomes.
Clinical Advice & FAQs
Billing Guidance
Is E77.1 a billable ICD-10 code?
Yes, E77.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E77.1?
Clinical documentation must specify the nature of Defects in glycoprotein degradation and any associated comorbidities for accurate reporting.
Cite this Clinical Reference